<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LOPERAMIDE HYDROCHLORIDE - loperamide hydrochloride capsule </strong><br>State of Florida DOH Central Pharmacy<br></p></div>
<h1>LOPERAMIDE HYDROCHLORIDE CAPSULES USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="INV-acf9806f-1b96-4f17-b5d6-33c8bc9f0216"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><a name="INV-d5c4853d-74ab-4000-bb70-cbdad960e3d0"></a>Loperamide hydrochloride is a white to slightly yellow powder and is freely soluble in methanol, isopropyl alcohol, chloroform and slightly soluble in water.</p>
<p><a name="INV-99b2cb87-588b-4db0-ab31-47d9896225eb"></a>Loperamide hydrochloride, 4-(p-chlorophenyl)-4-hydroxy-N,N-dimethyl-α,α-diphenyl-1-piperidinebutyramide monohydrochloride, is a synthetic antidiarrheal for oral use. Its structural formula is:</p>
<div class="Figure"><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ab07bfd1-d2d3-427a-866d-89a10d40a4e9&amp;name=LoperamideHydrochlorideCapsules-structure.jpg"></div>
<p><a name="INV-a6a418fd-7742-4b6e-874b-a0ee2f1392a4"></a>C<span class="Sub">29</span>H<span class="Sub">33</span>ClN<span class="Sub">2</span>O<span class="Sub">2</span>.HCl           M.W.  513.51</p>
<p><a name="INV-3490bb73-4130-4400-82ec-65f39cff1175"></a>Loperamide hydrochloride is available in 2 mg capsules.</p>
<p><a name="INV-76fdc056-8442-4956-bb0c-be099e23cc9c"></a>Each capsule, for oral administration, contains 2 mg loperamide hydrochloride.  Loperamide hydrochloride capsules USP also contain the inactive ingredients: pregelatinized corn starch, gelatin capsules, iron oxides, lactose monohydrate, magnesium stearate, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="INV-914f316f-a982-4c66-85ca-31d5f133eb9b"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><a name="INV-95ef4152-138b-4389-af30-1f64a66dfefe"></a><span class="Italics">In vitro</span> and animal studies show that loperamide hydrochloride acts by slowing intestinal motility and by affecting water and electrolyte movement through the bowel.  Loperamide binds to the opiate receptor in the gut wall. Consequently, it inhibits the release of acetylcholine and prostaglandins, thereby reducing peristalsis, and increasing intestinal transit time. Loperamide increases the tone of the anal sphincter, thereby reducing <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span> and urgency.</p>
<p><a name="INV-703b6f3c-4846-4734-a451-2e0c84624d58"></a>In man, loperamide hydrochloride prolongs the transit time of the intestinal contents.  It reduces the daily fecal volume, increases the viscosity and bulk density, and diminishes the loss of fluid and electrolytes.  Tolerance to the antidiarrheal effect has not been observed. Clinical studies have indicated that the apparent elimination half-life of loperamide hydrochloride in man is 10.8 hours with a range of 9.1 to 14.4 hours.  Plasma levels of unchanged drug remain below 2 nanograms per mL after the intake of a 2 mg loperamide hydrochloride capsule.  Plasma levels are highest approximately five hours after administration of the capsule and 2.5 hours after the liquid.  The peak plasma levels of loperamide were similar for both formulations.  Elimination of loperamide mainly occurs by oxidative N-demethylation. Cytochrome P450 (CYP450) isozymes, CYP2C8 and CYP3A4, are thought to play an important role in loperamide N-demethylation process since quercetin (CYP2C8 inhibitor) and ketoconazole (CYP3A4 inhibitor) significantly inhibited the N-demethylation process <span class="Italics">in vitro</span> by 40% and 90%, respectively. In addition, CYP2B6 and CYP2D6 appear to play a minor role in loperamide N-demethylation. Excretion of the unchanged loperamide and its metabolites mainly occurs through the feces. In those patients in whom biochemical and hematological parameters were monitored during clinical trials, no trends toward abnormality during loperamide hydrochloride therapy were noted.  Similarly, urinalyses, EKG and clinical ophthalmological examinations did not show trends toward abnormality.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="INV-28f9f95f-e3d8-4183-bad5-28e952c0aa0c"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><a name="INV-3236539f-1584-4959-b749-352a95144e1f"></a>Loperamide hydrochloride capsules are indicated for the control and symptomatic relief of acute nonspecific <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">chronic diarrhea</span> associated with <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>.  Loperamide hydrochloride capsules are also indicated for reducing the volume of discharge from ileostomies.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="INV-aab986fe-96bb-4616-9fdb-0161cbc65480"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><a name="INV-06a50917-b9ea-4a6e-8adb-09304b8f7c9f"></a>Loperamide hydrochloride capsules are contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to loperamide hydrochloride or to any of the excipients.</p>
<p><a name="INV-01ee4374-ac36-4c28-9f5d-941d26124c85"></a>Loperamide hydrochloride is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> in the absence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p><a name="INV-55b21707-378a-4155-8a0c-811f05df9faf"></a>Loperamide hydrochloride is not recommended in infants below 24 months of age.</p>
<p><a name="INV-b5cb1a57-dfd4-47f9-a5ac-c62f64ac9188"></a>Loperamide hydrochloride should not be used as the primary therapy:</p>
<ul class="Disc">
<li>in patients with acute <span class="product-label-link" type="condition" conceptid="4008089" conceptname="Dysentery">dysentery</span>, which is characterized by <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">blood in stools</span> and high <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>,</li>
<li>in patients with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">acute ulcerative colitis</span>,</li>
<li>in patients with bacterial <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> caused by invasive organisms including <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span>, Shigella, and Campylobacter,</li>
<li>in patients with <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> associated with the use of broad-spectrum antibiotics.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="INV-5d29426c-0889-4174-84d0-80f650f91086"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><a name="INV-87615e27-a0bc-4663-800e-1ee7190cc764"></a>Fluid and <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span> often occur in patients who have <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.  In such cases, administration of appropriate fluid and electrolytes is very important.  The use of loperamide hydrochloride does not preclude the need for appropriate fluid and electrolyte therapy.</p>
<p><a name="INV-5744eaa6-98be-4299-8667-2a257b3fd0f3"></a>In general, loperamide hydrochloride should not be used when inhibition of peristalsis is to be avoided due to the possible risk of significant sequelae including <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span> and toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>. Loperamide hydrochloride must be discontinued promptly when <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> or <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span> develop.</p>
<p><a name="INV-e717861c-6347-4983-9b29-01b8c0929f2c"></a>Treatment of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> with loperamide hydrochloride is only symptomatic. Whenever an underlying etiology can be determined, specific treatment should be given when appropriate (or when indicated).</p>
<p><a name="INV-b17b402d-c543-4eb9-b447-b60c89579535"></a>Patients with AIDS treated with loperamide hydrochloride for <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> should have therapy stopped at the earliest signs of abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>. There have been isolated reports of toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span> in AIDS patients with <span class="product-label-link" type="condition" conceptid="4192561" conceptname="Infectious colitis">infectious colitis</span> from both viral and bacterial pathogens treated with loperamide hydrochloride. {ref EDMS-PSDB-2564186, p. 12}</p>
<p><a name="INV-0128d56e-5530-4269-b4dc-beb3d6d830f9"></a>Loperamide hydrochloride should be used with special caution in young children because of the greater variability of response in this age group. <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span>, particularly in younger children, may further influence the variability of response to loperamide hydrochloride.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="INV-fa7686c0-7428-450f-abc2-962d0e5ed0b4"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="INV-5d5bac07-33f2-4d89-8696-c5ac636477cd"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First"><a name="INV-4a7f5f79-6b7b-469e-8aa4-d0b37d9c5c36"></a>Extremely rare <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> have been reported. In <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">acute diarrhea</span>, if clinical improvement is not observed in 48 hours, the administration of loperamide hydrochloride should be discontinued and patients should be advised to consult their physician. Although no pharmacokinetic data are available in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, loperamide hydrochloride should be used with caution in such patients because of reduced first pass metabolism. Patients with hepatic dysfunction should be monitored closely for signs of CNS toxicity. No pharmacokinetic data are available in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Since it has been reported that the majority of the drug is metabolized and metabolites or the unchanged drug is excreted mainly in the feces, dosage adjustments in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> are not required. No formal studies have been conducted to evaluate the pharmacokinetics of loperamide in elderly subjects. However, in two studies that enrolled elderly patients, there were no major differences in the drug disposition in elderly patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> relative to young patients.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="INV-54cb8bf2-f01e-4cdc-8737-7bef18d26944"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First"><a name="INV-e1286266-62f6-45ed-91a4-146e5bbb7318"></a>Patients should be advised to check with their physician if their <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> does not improve in 48 hours or if they note blood in their stools, develop a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or develop abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>.</p>
<p><a name="INV-7616cea7-202f-459c-86b0-5cf8e43ae8a4"></a><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Tiredness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> may occur in the setting of diarrheal syndromes treated with loperamide hydrochloride. Therefore, it is advisable to use caution when driving a car or operating machinery. (See <span class="Bold">ADVERSE REACTIONS</span>).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="INV-3118cd22-afdc-4d23-a74d-6636a944f8ae"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><a name="INV-9dbebf51-0032-4a1d-b950-9eb316eabe34"></a>Nonclinical data have shown that loperamide is a P-glycoprotein substrate. Concomitant administration of loperamide (16 mg single dose) with a 600 mg single dose of either quinidine or ritonavir, both of which are P-glycoprotein inhibitors, resulted in a 2 to 3 fold increase in loperamide plasma levels. Due to the potential for enhanced central effects when loperamide is coadministered with quinidine and with ritonavir, caution should be exercised when loperamide is administered at the recommended dosages (2 mg, up to 16 mg maximum daily dose) with P-glycoprotein inhibitors.</p>
<p><a name="INV-7fa099f8-c0a4-4cfc-baa5-35bd90478186"></a>When a single 16 mg dose of loperamide is coadministered with a 600 mg single dose of saquinavir, loperamide decreased saquinavir exposure by 54%, which may be of clinical relevance due to reduction of therapeutic efficacy of saquinavir. The effect of saquinavir on loperamide is of less clinical significance. Therefore, when loperamide is given with saquinavir, the therapeutic efficacy of saquinavir should be closely monitored.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="INV-9e4b257f-b384-40cb-ba90-e274430f6081"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><a name="INV-c75f2118-daf2-482f-981c-bd523c0b652a"></a>In an 18 month rat study with oral doses up to 40 mg/kg/day (21 times the maximum human dose of 16 mg/day, based on a body surface area comparison), there was no evidence of carcinogenesis.</p>
<p><a name="INV-39988a42-14db-4d40-8700-f922cb27aceb"></a>Loperamide was not genotoxic in the Ames test, the SOS chromotest in <span class="Italics">E. coli</span>, the dominant lethal test in female mice, or the mouse embryo cell transformation assay.</p>
<p><a name="INV-a7dfaf12-344e-4310-99f6-87b3e46c0512"></a>Fertility and reproductive performance was evaluated in rats using oral doses of 2.5, 10, and 40 mg/kg/day in one study, and 1, 5, 10, 20, and 40 mg/kg/day (females only) in a second study. Oral administration of 20 mg/kg/day (approximately 11 times the human dose based on a body surface area comparison) and higher produced strong impairment of female fertility. Treatment of female rats with up to 10 mg/kg/day p.o. (approximately 5 times the human dose based on a body surface area comparison) had no effect on fertility. Treatment of male rats with 40 mg/kg/day p.o. (approximately 21 times the human dose based on a body surface area comparison) produced impairment of male fertility, whereas administration of up to 10 mg/kg/day (approximately 5 times the human dose based on a body surface area comparison) had no effect.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="INV-aa26aef3-49ae-445d-89b5-af5977e39f3f"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="INV-92fbf070-91d7-4b63-9902-83ad4b20ced4"></a><a name="section-6.6"></a><p></p>
<h2>Teratogenic Effects</h2>
</div>
<div class="Section">
<a name="section-6.7"></a><p></p>
<h2>Pregnancy category B</h2>
<p class="First"><a name="INV-1fccecac-c9b5-4c31-86cd-8ba6ecca454d"></a>Teratology studies have been performed in rats using oral doses of 2.5, 10, and 40 mg/kg/day, and in rabbits using oral doses of 5, 20, and 40 mg/kg/day. These studies have revealed no evidence of impaired fertility or harm to the fetus at doses up to 10 mg/kg/day in rats (5 times the human dose based on body surface area comparison) and 40 mg/kg/day in rabbits (43 times the human dose based on body surface area comparison). Treatment of rats with 40 mg/kg/day p.o. (21 times the human dose based on a body surface area comparison) produced marked impairment of fertility. The studies produced no evidence of teratogenic activity. There are no adequate and well-controlled studies in pregnant women. Loperamide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="INV-46755cb4-0be5-4629-a987-c5368a475d7d"></a><a name="section-6.8"></a><p></p>
<h2>Non-teratogenic Effects</h2>
<p class="First"><a name="INV-9238877c-af8d-4e12-9805-3d1cbcdb87e1"></a>In a peri- and post-natal reproduction study in rats, oral administration of 40 mg/kg/day produced impairment of growth and survival of offspring.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="INV-7a71e39b-3053-4d51-84ce-18c2a8aab3dc"></a><a name="section-6.9"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First"><a name="INV-60457544-023b-4d3b-983b-b48f6e5b4a94"></a>Small amounts of loperamide may appear in human breast milk. Therefore, loperamide hydrochloride is not recommended during breast-feeding.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="INV-2adcd4ec-cf92-445f-b27e-f76c99ebb894"></a><a name="section-6.10"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First"><a name="INV-139d4fce-3329-4f2c-9e66-15b838988980"></a>See the <span class="Bold">WARNINGS </span>section for information on the greater variability of response in this age group.</p>
<p><a name="INV-2e9c8c0e-0b7b-4123-afe0-dd354d6e206c"></a>In case of accidental overdosage of loperamide hydrochloride by pediatric patients, see <span class="Bold">OVERDOSAGE </span>section for suggested treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="INV-876944fb-295f-4671-8e9d-13a3f149aabf"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section">
<a name="INV-937a6a9f-9fc1-40f9-889c-3e798fcbe455"></a><a name="section-7.1"></a><p></p>
<h2>Clinical Trial Data</h2>
<p class="First"><a name="INV-5e392755-7124-4f29-9836-cde89dd9afb0"></a>The adverse effects reported during clinical investigations of loperamide hydrochloride are difficult to distinguish from symptoms associated with the diarrheal syndrome. Adverse experiences recorded during clinical studies with loperamide hydrochloride were generally of a minor and self-limiting nature.  They were more commonly observed during the treatment of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">chronic diarrhea</span>.</p>
<p><a name="INV-cfe6168a-08dd-4d1c-807e-391fc2d49559"></a>The adverse events reported are summarized irrespective of the causality assessment of the investigators.</p>
<p><a name="INV-0a45cf6f-323d-4dbe-bc3d-9b1a202c1a3b"></a>1) Adverse events from 4 placebo-controlled studies in patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">acute diarrhea</span></p>
<p><a name="INV-28643df7-caa3-4bf7-9254-2f2db5aa1135"></a>The adverse events with an incidence of 1.0% or greater, which were reported at least as often in patients on loperamide hydrochloride as on placebo, are presented in the table below.</p>
<table border="1" frame="border">
<col align="left" width="1.00*">
<col align="left" width="1.00*">
<col align="left" width="1.00*">
<tbody class="Headless" valign="top">
<tr class="First" valign="top">
<td class="Botrule Lrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Acute Diarrhea</span></span></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Loperamide Hydrochloride</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Placebo</span></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">No. of treated patients</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">231</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">236</span></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Gastrointestinal AE%</span></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr class="Last" valign="top">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Botrule Rrule" align="center" valign="middle">2.6%</td>
<td class="Botrule Rrule" align="center" valign="middle">0.8%</td>
</tr>
</tbody>
</table>
<p><a name="INV-6c479451-93b3-4308-ac5c-2a7c56cc47ef"></a>The adverse events with an incidence of 1.0% or greater, which were more frequently reported in patients on placebo than on loperamide hydrochloride were: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">meteorism</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramp</span> and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">colic</span>.</p>
<p><a name="INV-c473334c-e950-4a33-854b-256f0ad25b46"></a>3) Adverse events from seventy-six controlled and uncontrolled studies in patients with acute or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">chronic diarrhea</span></p>
<p><a name="INV-53df5d97-b4c5-49a6-9563-ea1df0c57701"></a>The adverse events with an incidence of 1.0% or greater in patients from all studies are given in the table below.</p>
<table border="1" frame="border">
<col align="left" width="1.00*">
<col align="left" width="1.00*">
<col align="left" width="1.00*">
<tbody class="Headless" valign="top">
<tr class="First" valign="top">
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="middle"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Chronic Diarrhea</span></span></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule" align="center" valign="middle"><span class="Bold">Loperamide Hydrochloride</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Placebo</span></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">No. of treated patients</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">285</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">277</span></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Gastrointestinal AE%</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> </span></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Botrule Rrule" align="center" valign="middle">5.3%</td>
<td class="Botrule Rrule" align="center" valign="middle">0%</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Central and peripheral nervous system AE%</span></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr class="Last" valign="top">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center" valign="middle">1.4%</td>
<td class="Botrule Rrule" align="center" valign="middle">0.7%</td>
</tr>
</tbody>
</table>
<p><a name="INV-f5c83925-743a-464b-9eeb-a747b1c3e009"></a>The adverse events with an incidence of 1.0% or greater, which were more frequently reported in patients on placebo than on loperamide hydrochloride were: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">meteorism</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramp</span> and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">colic</span>.</p>
<p><a name="INV-1e0b0610-a770-42fc-b6d2-a1d4c4c52edb"></a>3) Adverse events from seventy-six controlled and uncontrolled studies in patients with acute or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">chronic diarrhea</span></p>
<p><a name="INV-0236dec4-1b60-42f1-bb47-8737e676ff32"></a>The adverse events with an incidence of 1.0% or greater in patients from all studies are given in the table below.</p>
<table border="1" frame="border">
<col align="left" width="1.00*">
<col align="left" width="1.00*">
<col align="left" width="1.00*">
<col align="left" width="1.00*">
<tfoot><tr class="First Last"><td align="left"><p class="First Footnote"><a name="INV-f082074f-2467-4c88-99c0-c6a3acdbb015"></a>a All patients in all studies, including those in which it was not specified if the adverse events    occurred in patients with acute or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">chronic diarrhea</span>.</p></td></tr></tfoot>
<tbody class="Headless" valign="top">
<tr class="First" valign="top">
<td class="Botrule Lrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Acute Diarrhea</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Chronic Diarrhea</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">All Studies</span><span class="Sup">a</span>
</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">No. of treated patients</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">1913</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">1371</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">3740</span></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Gastrointestinal AE%</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> </span></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Rrule" align="center" valign="middle">0.7%</td>
<td class="Botrule Rrule" align="center" valign="middle">3.2%</td>
<td class="Botrule Rrule" align="center" valign="middle">1.8%</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Botrule Rrule" align="center" valign="middle">1.6%</td>
<td class="Botrule Rrule" align="center" valign="middle">1.9%</td>
<td class="Botrule Rrule" align="center" valign="middle">1.7%</td>
</tr>
<tr class="Last" valign="top">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal cramps</span></td>
<td class="Botrule Rrule" align="center" valign="middle">0.5%</td>
<td class="Botrule Rrule" align="center" valign="middle">3.0%</td>
<td class="Botrule Rrule" align="center" valign="middle">1.4%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section">
<a name="INV-1f7ba6ae-44eb-4a6d-90f9-04eb939bfe09"></a><a name="section-7.2"></a><p></p>
<h2>Postmarketing Experience</h2>
<p class="First"><a name="INV-9d768d10-f0bf-474d-8d56-86fbcad9f20b"></a>The following adverse events have been reported:</p>
</div>
<div class="Section">
<a name="INV-e078855e-1d72-4044-8fae-d19b48aaf041"></a><a name="section-7.3"></a><p></p>
<h2>Skin and Subcutaneous Tissue Disorders</h2>
<p class="First"><a name="INV-5a81dd22-065b-4092-9128-23c651dc8310"></a><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and extremely rare cases of <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous eruption</span> including <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic Epidermal Necrolysis</span> have been reported with use of loperamide hydrochloride.</p>
</div>
<div class="Section">
<a name="INV-001b5c7b-0a4f-4cb3-b071-585ef8d1192e"></a><a name="section-7.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></h2>
<p class="First"><a name="INV-4c16fd29-2571-4f3e-b923-1f2270fc3b46"></a>Isolated occurrences of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> and in some cases severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have been reported with the use of loperamide hydrochloride.</p>
</div>
<div class="Section">
<a name="INV-c7a9a2fb-0c45-44a2-8b46-4c74d7e4e1ad"></a><a name="section-7.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></h2>
<p class="First"><a name="INV-ca113889-5de3-44eb-805d-eaf67bd95096"></a><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>, including toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span> (see <span class="Bold">CONTRAINDICATIONS </span>and <span class="Bold">WARNINGS</span>).</p>
</div>
<div class="Section">
<a name="INV-c8495c1a-9601-4d81-bc45-d56a0e889dd5"></a><a name="section-7.6"></a><p></p>
<h2>Renal and Urinary Disorders</h2>
<p class="First"><a name="INV-ac73b9fe-3663-4018-8987-46c9929585a6"></a><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span>.</p>
</div>
<div class="Section">
<a name="INV-23677817-d38a-4549-b314-3aa2fc62636b"></a><a name="section-7.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></h2>
<p class="First"><a name="INV-d2c8b7cf-e183-4a16-95ad-50fe2359afd4"></a><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
</div>
<div class="Section">
<a name="INV-9bff5807-773b-4a17-a9e5-9082df7c6f03"></a><a name="section-7.8"></a><p></p>
<h2>General Disorders and Administrative Site Conditions</h2>
<p class="First"><a name="INV-0c57efdc-4408-465f-b96f-2145f161c42b"></a><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Tiredness</span>.</p>
<p><a name="INV-c0d70354-b393-4528-a79f-2963855b76b6"></a>A number of the adverse events reported during the clinical investigations and postmarketing experience with loperamide are frequent symptoms of the underlying diarrheal syndrome (<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>). These symptoms are often difficult to distinguish from undesireable drug effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="INV-867f3618-c492-43d0-8785-aad02531be46"></a><a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34086-9">
<a name="INV-01f91294-3635-4aff-acfe-510e67248f6f"></a><a name="section-8.1"></a><p></p>
<h2>Abuse</h2>
<p class="First"><a name="INV-9c512baf-f2ff-45a7-b340-426c271a857d"></a>A specific clinical study designed to assess the abuse potential of loperamide at high doses resulted in a finding of extremely low abuse potential.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="INV-b50f3613-0b40-43de-9308-1059387b7b36"></a><a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First"><a name="INV-b53bb93a-7307-461f-8949-91fd6e63b333"></a>Studies in morphine-dependent monkeys demonstrated that loperamide hydrochloride at doses above those recommended for humans prevented signs of morphine withdrawal.  However, in humans, the naloxone challenge pupil test, which when positive indicates opiate-like effects, performed after a single high dose, or after more than two years of therapeutic use of loperamide hydrochloride, was negative. Orally administered loperamide hydrochloride capsules (loperamide formulated with magnesium stearate) is both highly insoluble and penetrates the CNS poorly.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="INV-a2fcea4b-da0e-4d74-8826-5513632bf577"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><a name="INV-dd15f70a-4237-47f0-9e45-ef88dab792ae"></a>In cases of overdosage, (including relative <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> due to hepatic dysfunction), <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> and <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> may occur.  Children may be more sensitive to CNS effects than adults.   Clinical trials have demonstrated that a slurry of activated charcoal administered promptly after ingestion of loperamide hydrochloride can reduce the amount of drug which is absorbed into the systemic circulation by as much as ninefold.  If <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occurs spontaneously upon ingestion, a slurry of 100 grams of activated charcoal should be administered orally as soon as fluids can be retained.</p>
<p><a name="INV-ea08536b-f2ed-4e13-8918-3a1e323fa284"></a>If <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> has not occurred, gastric lavage should be performed followed by administration of 100 grams of the activated charcoal slurry through the gastric tube.  In the event of overdosage, patients should be monitored for signs of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> for at least 24 hours.</p>
<p><a name="INV-57ba0343-2512-48fb-a642-466836b3b165"></a>If symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occur, naloxone can be given as an antidote. If responsive to naloxone, vital signs must be monitored carefully for recurrence of symptoms of drug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> for at least 24 hours after the last dose of naloxone.</p>
<p><a name="INV-836ee669-b5a6-4969-8f9a-75791d2d980b"></a>In view of the prolonged action of loperamide and the short duration (one to three hours) of naloxone, the patient must be monitored closely and treated repeatedly with naloxone as indicated.  Since relatively little drug is excreted in the urine, forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> is not expected to be effective for loperamide hydrochloride overdosage.</p>
<p><a name="INV-9ab46b3d-24c7-4636-a613-f22cac127509"></a>In clinical trials an adult who took three 20 mg doses within a 24 hour period was <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nauseated</span> after the second dose and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomited</span> after the third dose.  In studies designed to examine the potential for side effects, intentional ingestion of up to 60 mg of loperamide hydrochloride in a single dose to healthy subjects resulted in no significant adverse effects.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="INV-434d459d-e12b-4025-bbab-322e51d6eec2"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><a name="INV-47453401-1414-4536-a259-87bd49ebcf9b"></a>(1 capsule = 2 mg)</p>
<p><a name="INV-f2ad913b-ba5b-4775-bdc4-8a9f57b87572"></a>Patients should receive appropriate fluid and electrolyte replacement as needed.</p>
<div class="Section">
<a name="INV-8f58a21e-607e-4b26-a843-04f15f5a25cc"></a><a name="section-10.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Acute Diarrhea</span></h2>
</div>
<div class="Section">
<a name="INV-6e1c4064-c0af-4da2-962b-38ccbd0bcca0"></a><a name="section-10.2"></a><p></p>
<h2>Adults</h2>
<p class="First"><a name="INV-bb733a24-4fd1-4fb9-a95f-cdb65cfec4e1"></a>The recommended initial dose is 4 mg (two capsules) followed by 2 mg (one capsule) after each unformed stool.  Daily dosage should not exceed 16 mg (eight capsules).  Clinical improvement is usually observed within 48 hours.</p>
</div>
<div class="Section">
<a name="INV-372c385f-921e-46f7-9585-7827f1cad209"></a><a name="section-10.3"></a><p></p>
<h2>Children</h2>
<p class="First"><a name="INV-6745111d-63b4-41b1-8238-8558d1193274"></a>In children 2 to 5 years of age (20 kg or less), the non-prescription liquid formulation (loperamide hydrochloride for oral solution, 1 mg/5 mL) should be used; for ages 6 to 12, either loperamide hydrochloride capsules or loperamide hydrochloride for oral solution may be used.  For children 2 to 12 years of age, the following schedule for capsules or liquid will usually fulfill initial dosage requirements:</p>
<p><a name="INV-1f3f4b28-eefb-4847-ba82-619378d7cc59"></a><span class="Italics">Recommended First Day Dosage Schedule</span></p>
<p><a name="INV-1a1a3568-0434-4b30-b5d6-ec4709ca28d1"></a>Two to five years: 1 mg t.i.d. (3 mg daily dose) (13 to 20 kg)</p>
<p><a name="INV-3aff4d6e-d38c-43b9-98d7-4262e2e414f6"></a>Six to eight years: 2 mg b.i.d. (4 mg daily dose) (20 to 30 kg)</p>
<p><a name="INV-ef9417d2-438a-4342-8850-581a2f8c5aca"></a>Eight to twelve years: 2 mg t.i.d. (6 mg daily dose) (greater than 30 kg)</p>
<p><a name="INV-7e1895b4-5eb1-48a3-b710-5546fa2761c4"></a><span class="Italics">Recommended Subsequent Daily Dosage</span></p>
<p><a name="INV-43bbda52-ae37-4ce6-9ce0-a90d99d0107e"></a>Following the first treatment day, it is recommended that subsequent loperamide hydrochloride doses (1 mg/10 kg body weight) be administered only after a loose stool.  Total daily dosage should not exceed recommended dosages for the first day.</p>
</div>
<div class="Section">
<a name="INV-ca41e205-592d-4ebc-baa0-eb954dcddef7"></a><a name="section-10.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Chronic Diarrhea</span></h2>
</div>
<div class="Section">
<a name="INV-6b147380-88a5-4a92-aae4-5daa4caaf30d"></a><a name="section-10.5"></a><p></p>
<h2>Children</h2>
<p class="First"><a name="INV-92d7108c-befd-405b-913f-9d5f91231fa1"></a>Although loperamide hydrochloride has been studied in a limited number of children with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">chronic diarrhea</span>; the therapeutic dose for the treatment of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">chronic diarrhea</span> in a pediatric population has not been established.</p>
</div>
<div class="Section">
<a name="INV-b8fdbcd1-783d-430e-b1ac-7d06dfdcab1b"></a><a name="section-10.6"></a><p></p>
<h2>Adults</h2>
<p class="First"><a name="INV-1bd3e746-8069-4ed7-8cd4-c08df034e14e"></a>The recommended initial dose is 4 mg (two capsules) followed by 2 mg  (one capsule) after each unformed stool until <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> is controlled, after which the dosage of loperamide hydrochloride capsules should be reduced to meet individual requirements.  When the optimal daily dosage has been established, this amount may then be administered as a single dose or in divided doses.</p>
<p><a name="INV-ce3dfa75-7ae1-4327-8749-c5f716debcad"></a>The average daily maintenance dosage in clinical trials was 4 to 8 mg (two to four capsules).  A dosage of 16 mg (eight capsules) was rarely exceeded. If clinical improvement is not observed after treatment with 16 mg per day for at least 10 days, symptoms are unlikely to be controlled by further administration.  Loperamide hydrochloride capsules administration may be continued if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> cannot be adequately controlled with diet or specific treatment.</p>
</div>
<div class="Section">
<a name="INV-03e68c95-7a3e-4cdd-9871-0654e17c17ba"></a><a name="section-10.7"></a><p></p>
<h2>Children Under 2 Years</h2>
<p class="First"><a name="INV-97ee225e-f7b1-41bd-9545-38e6b79e2467"></a>The use of loperamide hydrochloride in children under 2 years is not recommended. There have been rare reports of <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> associated with abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>. Most of these reports occurred in the setting of acute <span class="product-label-link" type="condition" conceptid="4008089" conceptname="Dysentery">dysentery</span>, <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, and with very young children less than two years of age.</p>
</div>
<div class="Section">
<a name="INV-5585e246-d74d-44d9-b4c3-070e98b767d8"></a><a name="section-10.8"></a><p></p>
<h2>Elderly</h2>
<p class="First"><a name="INV-2738c160-f73f-4cf1-a898-cd64e0dd88c4"></a>No formal pharmacokinetic studies were conducted in elderly subjects. However, there were no major differences in the drug disposition in elderly patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> relative to young patients. No dosage adjustment is required for the elderly.</p>
</div>
<div class="Section">
<a name="INV-f8e5b1d2-5f18-4f16-bc9c-a1aa2241b474"></a><a name="section-10.9"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First"><a name="INV-536c4028-75ad-468f-aa82-e9daa005ac13"></a>No pharmacokinetic data are available in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Since the metabolites and the unchanged drug are mainly excreted in the feces, no dosage adjustment is required for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <span class="Bold">PRECAUTIONS</span>).</p>
</div>
<div class="Section">
<a name="INV-b71f6ed4-2b70-4178-a4d8-1725747342a2"></a><a name="section-10.10"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First"><a name="INV-35525370-ad1c-4a92-b577-c2451732586d"></a>Although no pharmacokinetic data are available in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, loperamide hydrochloride should be used with caution in such patients because of reduced first pass metabolism (see <span class="Bold">PRECAUTIONS</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="INV-349e1795-5b43-4efe-b887-c7ed630b867e"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><a name="INV-84fce128-94ef-42a5-b8f7-843efd1b4571"></a>Loperamide hydrochloride capsules USP, 2 mg are available as:</p>
<p><a name="INV-47dca6b5-6e84-4b76-9d72-42bd051f521f"></a>A light brown opaque body and dark brown opaque capsule, imprinted "93"-"311".</p>
<p><a name="INV-32fbbccd-860f-4fce-bdd3-cad406dabc90"></a>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].</p>
<p><a name="INV-ef98f37d-11f2-4aea-990e-86e0a5f2a8dd"></a>Dispense in a well-closed container, as defined in the USP, with a child-resistant closure (as required).</p>
<p><a name="INV-5ebc6183-8ff6-4af5-b41f-a1cfb9479204"></a>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</p>
<p>They are supplied by <span class="Bold"> State of Florida DOH Central Pharmacy</span> as follows:</p>
<table width="100%">
<colgroup>
<col width="13%">
<col width="25%">
<col width="25%">
<col width="25%">
<col width="12%">
</colgroup>
<thead><tr class="First Last" valign="bottom">
<td align="center"><span class="Bold">NDC</span></td>
<td align="center"><span class="Bold">Strength</span></td>
<td align="center"><span class="Bold">Quantity/Form</span></td>
<td align="center"><span class="Bold">Color</span></td>
<td align="center"><span class="Bold">Source NDC</span></td>
</tr></thead>
<tbody><tr class="First Last">
<td align="center">53808-0707-1</td>
<td align="center">2 mg</td>
<td align="center">30 TABLET</td>
<td align="center">light brown opaque,dark brown opaque</td>
<td align="center">0093-0311-05</td>
</tr></tbody>
</table>
<p>This product was Manufactured By:</p>
<p><span class="Bold"> TEVA PHARMACEUTICALS USA</span><br>Sellersville, PA 18960<br></p>
<p>And Repackaged By:</p>
<p><span class="Bold">State of Florida DOH Central Pharmacy</span><br>
104-2 Hamilton Park Drive<br>
Tallahassee, FL 32304<br>
United States<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>Label Image for 2mg 30 count pack</h1>
<div class="Figure"><img alt="Label Image for 2mg 30 count pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ab07bfd1-d2d3-427a-866d-89a10d40a4e9&amp;name=LOPERAMIDE%202mg%20(Teva).jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOPERAMIDE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">loperamide hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53808-0707(NDC:0093-0311)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LOPERAMIDE HYDROCHLORIDE</strong> (LOPERAMIDE) </td>
<td class="formItem">LOPERAMIDE HYDROCHLORIDE</td>
<td class="formItem">2 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (light brown opaque,dark brown opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">93;311</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53808-0707-1</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA073192</td>
<td class="formItem">07/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>State of Florida DOH Central Pharmacy
							(829348114)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">State of Florida DOH Central Pharmacy</td>
<td class="formItem"></td>
<td class="formItem">829348114</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>de0592d5-7e0e-41bb-af4d-62d1bdddb668</div>
<div>Set id: ab07bfd1-d2d3-427a-866d-89a10d40a4e9</div>
<div>Version: 2</div>
<div>Effective Time: 20100305</div>
</div>
</div> <div class="DistributorName">State of Florida DOH Central Pharmacy</div></p>
</body></html>
